In This Article:
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Botanix Pharmaceuticals (ASX:BOT) stock is up 156% in the last year, providing strong gains for shareholders. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.
So notwithstanding the buoyant share price, we think it's well worth asking whether Botanix Pharmaceuticals' cash burn is too risky. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.
See our latest analysis for Botanix Pharmaceuticals
Does Botanix Pharmaceuticals Have A Long Cash Runway?
A company's cash runway is calculated by dividing its cash hoard by its cash burn. As at June 2024, Botanix Pharmaceuticals had cash of AU$79m and no debt. In the last year, its cash burn was AU$26m. Therefore, from June 2024 it had 3.0 years of cash runway. Importantly, though, the one analyst we see covering the stock thinks that Botanix Pharmaceuticals will reach cashflow breakeven before then. If that happens, then the length of its cash runway, today, would become a moot point. Depicted below, you can see how its cash holdings have changed over time.
How Well Is Botanix Pharmaceuticals Growing?
Some investors might find it troubling that Botanix Pharmaceuticals is actually increasing its cash burn, which is up 37% in the last year. And we must say we find it concerning that operating revenue dropped 45% over the same period. Considering both these metrics, we're a little concerned about how the company is developing. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.
How Hard Would It Be For Botanix Pharmaceuticals To Raise More Cash For Growth?
Even though it seems like Botanix Pharmaceuticals is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Many companies end up issuing new shares to fund future growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).